Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MERiDiAN: Bevacizumab + Paclitaxel in HER2- Metastatic Breast Cancer
NCT01663727Phase 3Completed
- Sponsor
- Roche
- Start
- Aug 2012
- Primary completion
- Nov 2014
- Modality
- Monoclonal Antibodies
- Countries
- 16
01
Overview
Phase 3, randomised, double-blind trial in breast cancer comparing Paclitaxel + Bevacizumab with Paclitaxel + Placebo (2 arms). Primary endpoints: Progression Free Survival up to 117.7 weeks and Progression Free Survival in High Baseline Plasma VEGF-A Population up to 111.3 weeks. Started Aug 2012; status: completed.
02
Drugs
bevacizumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT01663727.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01663727.